Biotechnology

Techseriesinsight > Blog > News > Biotechnology

November 12, 2024
Business Wire
Biotechnology

Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial

Merck, a leading science and technology company, today announced that the Phase III MANEUVER trial of pimicotinib, an investigational medicine being developed by Abbisko Therapeutics Co., Ltd., met its...

November 8, 2024
PRNewswire
Biotechnology

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced the...

November 8, 2024
PRNewswire
Biotechnology

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor...

November 7, 2024
Business Wire
Biotechnology

Murata’s Revolutionary Stretchable Printed Circuit Elevates Wearable Medical Devices

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) reveals an innovative new Stretchable Printed Circuit (SPC) technology marking a significant development in printed circuit technology. Murata’s SPC represents the...

November 7, 2024
Business Wire
Biotechnology

MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through...

November 7, 2024
PRNewswire
Biotechnology

NAYO to Announce the Launch of Fully Automated Biobanking Solutions in Europe at Medica 2024

From 11 to 14 November, the 56th edition of MEDICA will take place in Düsseldorf, Germany. This year, MEDICA, one of the largest medical B2B trade fairs in the world, is...

November 7, 2024
PRNewswire
Biotechnology

Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders

Aditum Bio and Leads Biolabs today announced the formation of Oblenio Bio, which is being formed in conjunction with an exclusive option and license agreement to develop LBL-051, a...

November 6, 2024
Business Wire
Biotechnology

Acticor Biotech Provides an Update on the Current Receivership Proceedings

ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today provides an update on the current receivership...

November 6, 2024
PRNewswire
Biotechnology

Leads Biolabs Receives Orphan Drug Designation from the US FDA for LBL-034, a Uniquely Designed, Highly Differentiated Anti-GPRC5D/CD3 Bispecific Antibody, for the Treatment of Multiple Myeloma

On November 1, Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as “Leads Biolabs”) announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D and CD3 which is...

November 6, 2024
PRNewswire
Biotechnology

In-depth analysis showing robust Diamyd® treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress

The Immunology of Diabetes Society (IDS) Congress in Bruges, Belgium. The analysis will be presented at a Satellite Symposium organized by Abbott. The results support the robustness of the treatment...